Referred to the House Committee on Energy and Commerce.
This bill directs HHS, through the FDA, to increase transparency, stakeholder outreach, and guidance around human cell and tissue products (HCT/Ps). It requires FDA to publish educational materials and annual metrics, run workshops, open a public docket on modernization issues (including minimal manipulation and homologous use), and report recommendations to Congress by September 30, 2026.
Progressives stress protecting safety over speeding access
Relative to its intended legislative type, this bill is a focused administrative directive that clearly assigns responsibilities, deadlines, and reporting outputs to HHS/FDA to increase transparency and support modernization of HCT/P regulation.
This bill directs HHS, through the FDA, to increase transparency, stakeholder outreach, and guidance around human cell and tissue products (HCT/Ps).
It requires FDA to publish educational materials and annual metrics, run workshops, open a public docket on modernization issues (including minimal manipulation and homologous use), and report recommendations to Congress by September 30, 2026.
The bill also amends prior language to emphasize best practices for generating scientific data for stem cell and cellular therapies.
Content is narrow and administrative so it has reasonable prospects, but potential stakeholder disagreement and Senate procedures lower odds absent broad consensus or attachment to a larger vehicle.
Relative to its intended legislative type, this bill is a focused administrative directive that clearly assigns responsibilities, deadlines, and reporting outputs to HHS/FDA to increase transparency and support modernization of HCT/P regulation. It integrates with existing statute and creates tangible deliverables (public metrics, workshops, a docket, and a congressional report).
Progressives stress protecting safety over speeding access
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives stress protecting safety over speeding access
Likely cautiously supportive of clearer rules, transparency, and science-based guidance for HCT/Ps.
Concerned that efforts to 'modernize' could be used to relax safety standards or favor industry unless strong public health and access safeguards are explicit.
Generally favorable to streamlining and greater predictability for emerging therapies, provided the process is evidence-based and transparent.
Wants clear timelines, resource clarity, and a balanced stakeholder process to avoid unintended regulatory gaps or delays.
Likely supportive because the bill aims to modernize oversight and increase regulatory clarity for regenerative therapies.
Prefers changes that reduce unnecessary regulatory burden and speed access to safe treatments, while still preserving basic public health protections.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and administrative so it has reasonable prospects, but potential stakeholder disagreement and Senate procedures lower odds absent broad consensus or attachment to a larger vehicle.
The bill has not accumulated any surfaced votes yet.
Progressives stress protecting safety over speeding access
Content is narrow and administrative so it has reasonable prospects, but potential stakeholder disagreement and Senate procedures lower odd…
Relative to its intended legislative type, this bill is a focused administrative directive that clearly assigns responsibilities, deadlines, and reporting outputs to HHS/FDA to increase transparency and support moderniz…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.